{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:39:54Z","timestamp":1789058394643,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T00:00:00Z","timestamp":1672272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ijid.2022.12.039","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T02:30:17Z","timestamp":1672799417000},"page":"355-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia"],"prefix":"10.1016","volume":"128","author":[{"given":"Mahoko","family":"Ikeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3455-8291","authenticated-orcid":false,"given":"Shu","family":"Okugawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Kashiwabara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Moritoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Kanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Jubishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4072-9096","authenticated-orcid":false,"given":"Koh","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Mitsumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetoshi","family":"Igari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeya","family":"Tsutsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Araoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Yatera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2088-8724","authenticated-orcid":false,"given":"Yoshihiro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amato","family":"Otani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Wakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8804-0645","authenticated-orcid":false,"given":"Takayuki","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8960-8212","authenticated-orcid":false,"given":"Maho","family":"Adachi-Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Oyabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoi","family":"Kanematsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sohei","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-8968","authenticated-orcid":false,"given":"Yuichiro","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7516-8690","authenticated-orcid":false,"given":"Yasutaka","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunari","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichiro","family":"Sakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1667-9287","authenticated-orcid":false,"given":"Makoto","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5536-101X","authenticated-orcid":false,"given":"Hitoshi","family":"Kawasuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Hataji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Ichiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Seto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoji","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.12.039_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.ijid.2022.12.039_bib0002","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","author":"Solidarity Trial Consortium","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2022.12.039_bib0003","doi-asserted-by":"crossref","first-page":"24","DOI":"10.12793\/tcp.2022.30.e4","article-title":"Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19","volume":"30","author":"Cho","year":"2022","journal-title":"Transl Clin Pharmacol"},{"key":"10.1016\/j.ijid.2022.12.039_bib0004","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ijid.2022.12.039_bib0005","doi-asserted-by":"crossref","first-page":"e00720","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.12.039_bib0006","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/v12060629","article-title":"The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner","volume":"12","author":"Yamamoto","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ijid.2022.12.039_bib0007","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1093\/cid\/ciw571","article-title":"Clinical and virological characteristics of ebola virus disease patients treated with favipiravir (T-705)-Sierra Leone, 2014","volume":"63","author":"Bai","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.039_bib0008","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"10.1016\/j.ijid.2022.12.039_bib0009","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1128\/AAC.01156-16","article-title":"Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis","volume":"60","author":"Vanderlinden","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.12.039_bib0010","doi-asserted-by":"crossref","first-page":"26955","DOI":"10.1073\/pnas.2014441117","article-title":"Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity","volume":"117","author":"Kaptein","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ijid.2022.12.039_bib0011","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.ijid.2022.12.039_bib0012","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1186\/s13054-020-03078-z","article-title":"Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series","volume":"24","author":"Doi","year":"2020","journal-title":"Crit Care"},{"key":"10.1016\/j.ijid.2022.12.039_bib0013","doi-asserted-by":"crossref","first-page":"e192","DOI":"10.1016\/S1473-3099(20)30483-7","article-title":"WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research","volume":"20","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.039_bib0014","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/s41591-020-0869-5","article-title":"Temporal dynamics in viral shedding and transmissibility of COVID-19","volume":"26","author":"He","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2022.12.039_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.103856","article-title":"Randomised controlled trial of intravenous nafamostat mesylate in COVID pneumonitis: phase 1b\/2a experimental study to investigate safety, Pharmacokinetics and Pharmacodynamics","volume":"76","author":"Quinn","year":"2022","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ijid.2022.12.039_bib0016","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00970-21","article-title":"The TMPRSS2 inhibitor nafamostat reduces SARS-CoV-2 pulmonary infection in mouse models of COVID-19","volume":"12","author":"Li","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.ijid.2022.12.039_bib0017","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijid.2022.04.035","article-title":"The efficacy and adverse effects of favipiravir on patients with COVID-19: a systematic review and meta-analysis of published clinical trials and observational studies","volume":"120","author":"Hung","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2022.12.039_bib0018","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101169","article-title":"Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised phase II clinical trial","volume":"41","author":"Zhuravel","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijid.2022.12.039_bib0019","doi-asserted-by":"crossref","unstructured":"Chupp G, Spichler-Moffarah A, S\u00f8gaard OS, Esserman D, Dziura J, Danzig L, et\u00a0al. A Phase 2 randomized, double-blind, placebo-controlled trial of oral camostat mesylate for early treatment of COVID-19 outpatients showed shorter illness course and attenuation of loss of smell and taste. medRxiv. 31 January 2022. https:\/\/www.medrxiv.org\/content\/10.1101\/2022.01.28.22270035v1 [accessed 5 November 2022].","DOI":"10.1101\/2022.01.28.22270035"},{"key":"10.1016\/j.ijid.2022.12.039_bib0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaci.2006.02.047","article-title":"Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma","volume":"118","author":"Chen","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ijid.2022.12.039_bib0021","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/jmv.26700","article-title":"The clinically used serine protease inhibitor nafamostat reduces influenza virus replication and cytokine production in human airway epithelial cells and viral replication in mice","volume":"93","author":"Yamaya","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.ijid.2022.12.039_bib0022","first-page":"164","article-title":"Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system","volume":"15","author":"Hitomi","year":"1985","journal-title":"Haemostasis"},{"key":"10.1016\/j.ijid.2022.12.039_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100849","article-title":"Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial","volume":"35","author":"Gunst","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ijid.2022.12.039_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00439-22","article-title":"Dual inhibition of vacuolar-ATPase and TMPRSS2 is required for complete blockade of SARS-CoV-2 entry into cells","volume":"66","author":"Icho","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.12.039_bib0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s12974-021-02357-y","article-title":"Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illness","volume":"19","author":"Yates","year":"2022","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.ijid.2022.12.039_bib0026","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s40121-021-00517-4","article-title":"Efficacy and safety of favipiravir in moderate COVID-19 pneumonia patients without oxygen therapy: a randomized, Phase III clinical trial","volume":"10","author":"Shinkai","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2022.12.039_bib0027","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s00216-008-2054-4","article-title":"A method for quantifying the unstable and highly polar drug nafamostat mesilate in human plasma with optimized solid-phase extraction and ESI-MS detection: more accurate evaluation for pharmacokinetic study","volume":"391","author":"Cao","year":"2008","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.ijid.2022.12.039_bib0028","first-page":"767","article-title":"[Pharmacokinetics studies of nafamostat mesilate (FUT), a synthetic protease inhibitor, which has been used for the treatments of DIC and acute pancreatitis, and as an anticoagulant in extracorporeal circulation]","volume":"27","author":"Tsukagoshi","year":"2000","journal-title":"Gan To Kagaku Ryoho"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222006841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T08:13:46Z","timestamp":1761120826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222006841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":28,"alternative-id":["S1201971222006841"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.12.039","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}